Further, we found that TBB treatment increases both the binding of IKZF1 (Figure 5B) and the presence of the H3K9me3 histone modification (Figure 6E) at the CRLF2 promoter in primary ALL cells. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.